ANGO Financial Facts
Research and development: 5.59MOther expense: -733K
See Full Income Statement
OTHER ASSETS: 3.36M
INTANGIBLE ASSETS, less accumulated amortization: 45.71M
See Full Balance Sheet
AngioDynamics (ANGO) Earnings
|
Expand Research on ANGO
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +112.5% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -31.0% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 7/12/22 |  |
Q422 | N/A | $0.01 | N/A | N/A | $82.92M | N/A | N/A | N/A | |
| 4/7/22 | |
Q322 | $0.03 | -$0.01 | +$0.04 | $74M | $76.32M | N/A |  | | Details |
| 1/6/22 | |
Q222 | -$0.02 | $0.00 | -$0.02 | $78.3M | $77.88M | N/A | | | Details |
| 9/30/21 | |
Q122 | -$0.02 | -$0.04 | +$0.02 | $77M | $71.31M | N/A | | | Details |
| 7/13/21 | |
Q421 | $0.00 | $0.00 | $0.00 | $76.8M | $72.68M | N/A | | | Details |
| 3/30/21 | |
Q321 | $0.02 | -$0.02 | +$0.04 | $71.2M | $68.95M | N/A | | | Details |
| 1/7/21 | |
Q221 | $0.01 | -$0.02 | +$0.03 | $72.8M | $67.35M | N/A | | | Details |
| 9/29/20 | |
Q121 | $0.02 | -$0.07 | +$0.09 | $70.2M | $65.1M | N/A | | | Details |
